Clinical Trials Browser

Phase 1/2 × Terminated × givinostat hydrochloride × Clear all

NCT00496431 2022-01-27

phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

Phase 1/2 Terminated

Hodgkin Disease